May. 20 at 2:03 AM
$AMPH In April 2026, the FDA classified the International Medication Systems (IMS) manufacturing facility in South El Monte, California—a subsidiary of Amphastar Pharmaceuticals—as Official Action Indicated (OAI). This classification follows a routine FDA facility inspection in December 2025 and indicates that the agency found objectionable conditions and recommends regulatory or administrative action.
